Abstract
Enoyl-acyl carrier protein reductase (ENR), a critical enzyme in type II fatty acid biosynthesis, is a promising target for drug discovery against hepatocyte-stage Plasmodium falciparum. In order to identify PfENR-specific inhibitors, we docked 70 FDA-approved, bioactive, and/or natural product small molecules known to inhibit the growth of whole-cell blood-stage P. falciparum into several PfENR crystallographic structures. Subsequent in vitro activity assays identified a noncompetitive low-micromolar PfENR inhibitor, celastrol, from this set of compounds.
Keywords:
Celastrol; Enoyl-acyl carrier protein reductase; Malaria; Plasmodium falciparum; in silico.
Copyright © 2014. Published by Elsevier Ltd.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Antimalarials / chemistry*
-
Antimalarials / pharmacology*
-
Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / antagonists & inhibitors*
-
Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / chemistry
-
Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / metabolism
-
Humans
-
Malaria, Falciparum / drug therapy
-
Malaria, Falciparum / microbiology
-
Molecular Docking Simulation
-
Pentacyclic Triterpenes
-
Plasmodium falciparum / chemistry
-
Plasmodium falciparum / drug effects
-
Plasmodium falciparum / enzymology*
-
Triterpenes / chemistry*
-
Triterpenes / pharmacology*
Substances
-
Antimalarials
-
Pentacyclic Triterpenes
-
Triterpenes
-
Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)
-
celastrol